Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

Castration-resistant prostate cancer

  • You have access
    Patients Diagnosed With Metastatic Castration-sensitive Prostate Cancer and High Serum Lactate Dehydrogenase Levels Did Not Receive an Adequate Dose of Cabazitaxel
    YASUSHI NAKAI, KENTA ONISHI, YORIAKI KAGEBAYASHI, KEN FUJIMOTO, AKIHIDE HIRAYAMA, MASAKI HARAMOTO, ATSUSHI TOMIOKA, KENJI OTSUKA, EIJIRO OKAJIMA, TAKESHI OTANI, YOSHIHIRO MATSUMOTO, YUKINARI HOSOKAWA, MASAHIRO TANAKA, TOSHIHISA SAKA, NOBUO OYAMA, SHUYA HIRAO, KIYOHIDE FUJIMOTO and NOBUMICHI TANAKA
    Anticancer Research September 2025, 45 (9) 3953-3960; DOI: https://doi.org/10.21873/anticanres.17753
  • Open Access
    NK Cells Can Target Castration-resistant Prostate Cancer Stem Cells With the Involvement of Degranulation Pathway
    ASUKA HATTORI, TAIGA SEKI, KAZUNORI KATO, NANTIGA VIRGONA, YUICHI MIYAKOSHI, KAKERU KOHNO and TOMOHIRO YANO
    Anticancer Research August 2025, 45 (8) 3197-3207; DOI: https://doi.org/10.21873/anticanres.17682
  • You have access
    Efficacy of Combination Therapy With Radium-223 and Enzalutamide in Castration-resistant Prostate Cancer With Bone Metastases
    NAOTO WAKITA, TAKUTO HARA, KOTARO SUZUKI, TOMOAKI TERAKAWA, JUN TEISHIMA, YUZO NAKANO and HIDEAKI MIYAKE
    Anticancer Research June 2024, 44 (6) 2627-2635; DOI: https://doi.org/10.21873/anticanres.17069
  • You have access
    Copy Number Gain in Androgen Receptors Predicts the Poor Prognosis in Japanese Castration-resistant Prostate Cancer
    SHINICHI SAKAMOTO, KEISUKE ANDO, SANGJON PAE, XUE ZHAO, KAZUKO SAKAI, KODAI SATO, SHINPEI SAITO, YASUTAKA YAMADA, JUNRYO RII, YUSUKE GOTO, TOMOKAZU SAZUKA, YUSUKE IMAMURA, NAOHIKO ANZAI, KOICHIRO AKAKURA, KAZUTO NISHIO and TOMOHIKO ICHIKAWA
    Anticancer Research February 2024, 44 (2) 639-647; DOI: https://doi.org/10.21873/anticanres.16853
  • Open Access
    Initial-to-nadir Prostate-specific Antigen Ratio Predicts Response to First-line Enzalutamide in Metastatic Castration-resistant Prostate Cancer
    YUJIRO NAGATA, KAZUMASA JOJIMA, TAKUO MATSUKAWA, IKKO TOMISAKI and NAOHIRO FUJIMOTO
    Anticancer Research October 2023, 43 (10) 4573-4581; DOI: https://doi.org/10.21873/anticanres.16651
  • You have access
    Is it Necessary to Treat all Metastatic Prostate Cancer With Upfront Androgen Receptor Axis-targeted Agents?
    RYUNOSUKE NAKAGAWA, HIROAKI IWAMOTO, RENATO NAITO, SUGURU KADOMOTO, HIROSHI YAEGASHI, SHOHEI KAWAGUCHI, TAKAHIRO NOHARA, KAZUYOSHI SHIGEHARA, KOUJI IZUMI, YOSHIFUMI KADONO and ATSUSHI MIZOKAMI
    Anticancer Research March 2023, 43 (3) 1351-1359; DOI: https://doi.org/10.21873/anticanres.16283
  • You have access
    Chalcone Derivatives Suppress Proliferation and Migration of Castration-resistant Prostate Cancer Cells Through FAK-mediated DNA Damage
    HAINIAO XIAO, ZHIGANG WU, QINQUAN WANG, CHAOFENG ZHOU, FENG LU and YUNBEI XIAO
    Anticancer Research January 2023, 43 (1) 389-403; DOI: https://doi.org/10.21873/anticanres.16174
  • You have access
    Enzalutamide or Abiraterone Acetate With Prednisone in the Treatment of Metastatic Castration-resistant Prostate Cancer in Real-life Clinical Practice: A Long-term Single Institution Experience
    ONDREJ FIALA, PETR HOSEK, HANA KORUNKOVA, MILAN HORA, JIRI KOLAR, JINDRA WINDRICHOVA, ONDREJ SOREJS, ONDREJ TOPOLCAN, IVAN TRAVNICEK, HANA SEDLACKOVA and JINDRICH FINEK
    Anticancer Research January 2023, 43 (1) 463-471; DOI: https://doi.org/10.21873/anticanres.16183
  • You have access
    Efficacy and Safety of Radium-223 for Castration-resistant Prostate Cancer With Bone Metastasis Before and After Docetaxel
    KO OKABE, NAOKI TERADA, TATSUYA SHIRAKAWA, CHIE ONIZUKA, TOMOYA KIMURA, YASUHIRO YAMASHITA, ISAMU OTUKA, TAKASHI UENO, MASAFUMI NAGANO, HIROKI TAKAMORI, SHOICHIRO MUKAI and TOSHIYUKI KAMOTO
    Anticancer Research October 2022, 42 (10) 4981-4987; DOI: https://doi.org/10.21873/anticanres.16005
  • You have access
    Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?
    NAOHIRO FUJIMOTO, KENICHI HARADA, MASAKI SHIOTA, IKKO TOMISAKI, AKINORI MINATO, YUJIRO NAGATA, RIEKO KIMURO, MIRII HARADA and MASATO FUJISAWA
    Anticancer Research October 2021, 41 (10) 4687-4695; DOI: https://doi.org/10.21873/anticanres.15282

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
Anticancer Research

© 2025 Anticancer Research

Powered by HighWire